Alexander Koppara1,2, Ingo Frommann1,2, Alexandra Polcher1,2, Mario A Parra3,4, Wolfgang Maier1,2, Frank Jessen1,2, Thomas Klockgether2,5, Michael Wagner1,2. 1. Department of Psychiatry and Psychotherapy, Rheinische-Friedrich-Wilhelms University Bonn, Bonn, Germany. 2. German Center for Neurodegenerative Diseases (DZNE) Bonn, Bonn, Germany. 3. Human Cognitive Neuroscience and Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK. 4. UDP-INECO Foundation Core on Neuroscience (UIFCoN), Diego Portales University, Santiago, Chile. 5. Department of Neurology, Rheinische-Friedrich-Wilhelms University Bonn, Bonn, Germany.
Abstract
BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD. OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding. METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts. RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p < 0.0001). DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.
BACKGROUND: Feature binding is a sensitive and specific cognitive marker for Alzheimer's disease (AD). Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are clinical categories associated with an increased risk for AD. OBJECTIVE: To investigate whether the SCD and MCI group are impaired with regard to feature binding. METHODS: The feature binding test was administered to memory clinic patients with either SCD (n = 19, mean MMSE: 29.2) or with MCI (n = 23, mean MMSE: 26.5), and to a group of healthy controls (HC, n = 23, mean MMSE: 29.0). Participants were assessed with the CERAD Plus neuropsychological test battery. Cognitive performance of the three groups was compared by ANCOVA with age, gender and education as covariates and planned contrasts. RESULTS: Groups differed in the binding condition. Planned contrasts showed significant differences in adjusted means between HC and SCD (p = 0.003), as well as between HC and MCI (p < 0.0001). DISCUSSION: The feature binding task detects subtle cognitive impairments in participants with SCD, who are unimpaired in traditional neuropsychological testing. This corroborates the use of feature binding tests in preclinical AD studies and suggests that specific cognitive deficits can be found in SCD. Future studies incorporating AD biomarkers and longitudinal follow-up are needed to further establish the clinical utility of feature binding.
Authors: Andrea Tales; Frank Jessen; Christopher Butler; Gordon Wilcock; Judith Phillips; Tony Bayer Journal: J Alzheimers Dis Date: 2015-09-24 Impact factor: 4.472
Authors: Frank Jessen; Annika Spottke; Henning Boecker; Frederic Brosseron; Katharina Buerger; Cihan Catak; Klaus Fliessbach; Christiana Franke; Manuel Fuentes; Michael T Heneka; Daniel Janowitz; Ingo Kilimann; Christoph Laske; Felix Menne; Peter Nestor; Oliver Peters; Josef Priller; Verena Pross; Alfredo Ramirez; Anja Schneider; Oliver Speck; Eike Jakob Spruth; Stefan Teipel; Ruth Vukovich; Christine Westerteicher; Jens Wiltfang; Steffen Wolfsgruber; Michael Wagner; Emrah Düzel Journal: Alzheimers Res Ther Date: 2018-02-07 Impact factor: 6.982
Authors: Pierre-Yves Jonin; Clara Calia; Sophie Muratot; Serge Belliard; Quentin Duché; Emmanuel J Barbeau; Mario A Parra Journal: Cortex Date: 2018-08-27 Impact factor: 4.027